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Updated genetic testing of  Italian patients referred with a clinical diagnosis of primary 
hyperoxaluria.  
 
ABSTRACT  
  
Background: Primary hyperoxaluria (PH) is a rare autosomal recessive disease commonly arising in 
childhood and presenting with nephrolithiasis, nephrocalcinosis and/or chronic renal failure. Three 
responsible genes are known: alanine-glyoxylate aminotransferase (AGXT, PH type 1), glyoxylate 
reductase/hydroxypyruvate reductase (GRHPR, PH type 2), and 4-hydroxy-2-oxoglutarate aldolase 
(HOGA1, PH type 3). In our centre at the end of 2014 molecular diagnosis of PH1 had been 
performed in 80 patients, while one patient received a PH2 diagnosis. 
Material and Methods: Fifteen patients referred to our Centre and suspected to have PH on clinical 
grounds were negative for pathogenic variants in the entire coding sequence and exon-intron 
boundaries of the AGXT gene. Therefore, we extended the analysis to the AGXT promoter region 
and the GRHPR and HOGA1 genes.  
Results: Two patients were heterozygous for two novel AGXT-promoter variants (c.-647C>T, c.-
424C>T) that were probably non pathogenic. One patient was homozygous for a novel HOGA1 
variant of intron 2 (c.341-81delT), whose pathogenicity predicted by in silico splicing tools was not 
confirmed by a minigene splicing assay in COS-7 and HEK293T cells.  
Conclusion: New genetic subtypes of PH can be hypothesized in our patients, that may be caused 
by mutations in (an)other gene/genes encoding proteins of glyoxylate metabolism. 
Alternatively, some kind of mutations (e.g. deletions/duplications, deep intronic splicing regulatory 
variants) could be missed in a few cases, similarly to other genetic diseases. 
 
Keywords: AGXT, glyoxylate metabolism, GRHPR, HOGA1, primary hyperoxaluria.  
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Abbreviation footnote:  
AGT: alanine-glyoxylate aminotransferase  
ESRD: end stage renal disease 
GFR: glomerular filtration rate 
GRHPR: glyoxylate reductase/hydroxypyruvate reductase  
GO: glycolate oxidase 
HOGA: 4-hydroxy-2-oxoglutarate aldolase 
LDH: lactate dehydrogenase  
nv: normal value 
PH: primary hyperoxaluria 
PH1: primary hyperoxaluria type 1 
PH2: primary hyperoxaluria type 2 
PH3: primary hyperoxaluria type 3 
Pox: plasma oxalate 
Uox: urinary oxalate 
WT: wild type 
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Introduction  
 
Primary hyperoxaluria (PH) is a rare autosomal recessive disease (prevalence 1-3x10-6)  with 
onset mainly in childhood [1]. It is characterized by increased levels of urinary and plasma oxalate, 
nephrolithiasis and/or nephrocalcinosis leading to end stage renal disease (ESRD) and systemic 
oxalosis [2]. Three types of PH are currently known, but further genetic heterogeneity has been 
hypothesized, since in some patients the clinical suspicion of PH is not confirmed by molecular 
analysis [1].  
 PH1 (MIM #259900), the most frequent and severe form, is caused by an impaired function of 
the alanine-glyoxylate aminotransferase enzyme (AGT), encoded by the AGXT gene (MIM 
*604285) [3,4]. Deficiency of glyoxylate reductase/hydroxypyruvate reductase enzyme, encoded by 
the GRHPR gene (MIM *604296), is responsible of PH2 (MIM #260000) [5]. PH2 patients rarely 
develop systemic oxalosis and only 20% of them progress to ESRD [5-7]. A peculiar biochemical 
PH2 characteristic is the presence of  increased  urinary L-glyceric acid [8]. PH3 (MIM #613616) is 
caused by mutations in the HOGA1 gene (MIM*613597), that encodes the mitochondrial enzyme 4-
hydroxy-2-oxoglutarate aldolase (HOGA), catalysing the final step of 4-hydroxy-2-oxoglutarate 
catabolism to glyoxylate and pyruvate [9]. The age at onset of signs and symptoms is similar to 
those of PH1 and PH2, but in most PH3 patients a clinical remission is observed in the adult, 
despite the persistence of high oxalemia and oxaluria levels [10,11]. 
High 24-hour urinary oxalate (Uox) levels are suggestive of PH in the absence of secondary 
causes of hyperoxaluria, such as inflammatory bowel diseases or intestinal malabsorption [1,4]. 
Another important parameter is the molar urinary Oxalate/Creatinine ratio, that should always be 
related to the age of the subject, since higher ratios are observed in children due to lower urinary 
creatinine concentrations [12]. In patients with ESRD, Uox can be within the normal range or even 
below because of the decreased glomerular filtration; in such cases Plasma Oxalate (Pox) 
measurement it is preferable [1]. 
The assay of AGXT activity on hepatic tissue, once considered as the gold standard in PH1 
diagnosis, is at present rarely performed, since the less invasive genetic testing has become 
available. In addition, the clinical presentation of the three PH types is largely overlapping, thus 
genetic analysis is an important tool to differentiate the three subtypes. According to the current 
recommendations, a different treatment is indicated for each PH type: combined kidney-liver 
transplantation is recommended only for PH1 [3], while isolated kidney transplantation is mostly 
performed in PH2, and no specific need of transplantation has been so far reported for PH3. 
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Moreover, AGXT genotype can help in predicting the effectiveness of vitamin B6 supplementation 
[1]. 
Here we report the 80 Italian PH1 and the only PH2 patients currently known in our Country, 
collected until the end of 2014 and we describe a group of 15 patients with a clinical suspicion of 
PH but without a mutation in the three known genes. Moreover, we characterize the functional 
assay of a HOGA1 variant of unknown pathogenicity. 
 
Material and methods 
 
Major clinical criteria to suspect PH included nephrolithiasis, nephrocalcinosis and precocious age 
at onset of symptoms, while macro/micro hematuria and recurrent urinary infections were 
considered as indirect signs of renal stone disease. Glomerular filtration rate (GFR) in children was 
evaluated using the appropriate Schwartz's formula according to creatinine dosage assay while for 
adults the MDRD or CKD-EPI was employed. Urinary tract anomalies and secondary causes of 
hyperoxaluria, such as intestinal malabsorption and inflammatory bowel disease, were excluded. 
Biochemical parameters included oxalemia, oxaluria, urinary glycolate (see ref [12] for normal 
values) and renal function (plasma creatinine and GFR). Data about parents' consanguinity and the 
familiar history were collected.  
 
Sanger sequencing of AGXT, GRHPR and HOGA1 genes  
 
Genomic DNA was extracted from peripheral blood using Maxwell System (Promega, WI, USA). 
Amplification and sequencing primers and protocols are available on request. Analysis of AGXT 
was performed at first; in case of negative result GRPHR, HOGA1 and the AGXT promoter-region 
have been analyzed. 
 
Minigene assay 
 
In vitro analysis of the potential splice-site HOGA1 c.341-81delT variant was performed using the 
pSPL3 splicing assay previously described [10,13,14]. 
A 449 bp genomic fragment of DNA centered on the change c.341-81delT from the patient and one  
from a wild type (WT) control sample were amplified and the PCR products were cloned into a TA-
vector (pGEM-T Easy Vector - Promega, Madison, WI, USA) and transformed into DH5a bacterial 
cells (RBC Bioscience, Chung Ho City, Taiwan). Plasmids containing the WT or the variant 
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sequence were extracted and digested with EcoRI and NotI restriction endonuclease. Inserts were 
sub-cloned into a pSPL3 exon-trapping vector (Life Technologies, Paisley, UK). PSPL3 minigene 
constructs containing the genomic change c.341-81delT and the WT sequence were extracted from 
DH5a bacterial cells and transfected into both COS-7 and HEK293T cells. After 24 h, total RNA 
was extracted and retro-transcribed with the Cells-To-Ct kit (Life Technologies). The cDNA was 
amplified by standard and nested PCR and the different amplicons were separated on a TBE-
agarose 1.8% gel (Online Resource, protocols available upon request). 
 
 
Results 
 
Clinical and biochemical data of the 105 patients referred to our Centre were evaluated 
according to recent guidelines [3] and the clinical suspicion of PH was supported by clinical 
findings in 96 of them. A different diagnosis was established in nine patients: four were affected by 
secondary hyperoxaluria, three by kidney malformations; one was diagnosed as Dent and one as 
Pseudo-Bartter syndrome.  
 
Clinical, biochemical and genetic characteristics of PH1 and PH2 patients 
 
At the end of 2014 the Italian database included 80 PH1 patients (28 females and 52 males) and one 
PH2 patient. Thirteen patients (16%) had consanguineous parents (information not available for 16 
patients), a familiar history was reported in 30 cases (24.6%). 
 
Symptoms at onset were mainly nephrolithiasis (52.5%) and nephrocalcinosis (35.2%). Three 
patients were diagnosed at family screening before symptoms developed. Median age at onset was 4 
years (range 0.5-11.5), median age at diagnosis was 11 years (range 4-30).  
Biochemical measurements at diagnosis were not available for 11 patients. Median Pox at diagnosis 
was 130 umol/L (24-187; normal values (nv): <2.5 umol/L; data not available in 23 patients) and 
median Uox 230 uM/mM creat per day (151-435.5; data not available in 41 patients).  
Liver biopsy for AGT activity measurement was available for 35 patients: mean residual AGT 
activity was negligible in 27, only in 8/35 (22.9%) samples a partial AGT activity was detected 
(mean: 39±13% of the normal).  
At the end of 2014, 55 patients had ESRD and the median age was 14 years (range 4-31). 
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Ten patients had a kidney-only transplant and two of them had a second kidney-only transplant. In 
another six cases a second kidney transplant was combined with liver transplant. Median age at first 
kidney transplant was 18 years old (range 10-35). In 17 patients a combined kidney-liver transplant 
was performed and in one a sequential kidney-liver transplant. Median age at kidney-liver 
transplant was 13 years old (range 4-27). In two cases a second kidney transplant was performed 
after the combined kidney-liver. One patient underwent two combined kidney-liver transplants. In 
one case a preemptive liver transplant was performed.  
As reported in literature, also in the Italian cohort the most common AGXT mutation is 
p.Gly170Arg (28% of the alleles) detected in 14 patients in homozygosis, in 11 in heterozygosis 
with a missense mutation and in four with a null mutation. 
The patient affected by PH2 suffered from recurrent nephrolithiasis since 9 years old. Neither 
familiar history of nephrolithiasis nor parents consanguinity was referred. Uox was 77 uM/mM 
creat per day at 31 years of age. Urinary L-glycerate was 4600 uM/24h (nv <30). His renal 
functional was normal until the end of 2014. Molecular analysis revealed the c.295C>T, p.Arg99* 
mutation in GRHPR gene in homozygosis. 
 
 
Clinical, biochemical and genetic characteristics of non-PH1 non-PH2 patients 
 
Among the fifteen mutation-negative patients (six males), eleven (73%) had nephrolithiasis (two 
bilateral), five (33%) had nephrocalcinosis and one was affected with both. The median age at onset 
of symptoms was 5.3 years (range: 2 months-32 years). Renal function was normal in nine; three 
had already progressed to ESRD; data were not available for three patients. Three patients had 
recurrent urinary infections, four hematuria (three of them microhematuria). 
Uox was available for eight patients; in children < 12 years, mean oxaluria was 190.3 mmol/mmol 
creatinine (range: 106-366) while in adults 78 mmol/mmol creatinine (nv < 40 mmol/mmol 
creatinine [12]). 
Mean Pox was available in four children (7.3 µmol/L) and three adults (33.9 µmol/L) in ESRD state.  
Urinary calcium in patients with preserved renal function was in the normal range.  
Four patients had family history of nephrolithiasis (Online Resource table 1). 
 
Among these patients no pathogenic mutations in the three PH genes were found.  
Sequencing of the AGXT promoter revealed two novel variants: one patient was heterozygous 
for the c.-647C>T variant and another patient resulted heterozygous for the c.-424C>T variant. 
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Neither variants were reported in dbSNP141, 1000Genomes (http://www.1000genomes.org, 
29/07/2015), EVS (Exome variant server, 29/07/2015), EXAC (29/07/2015) and, because they do 
not lie in any known regulatory site, were classified as probably non pathogenic. 
A third patient carried a homozygous variant in the intron 2 of HOGA1 (c.341-81delT). This 
variant is not reported in EXAC Browser or EVS, but it is reported in dbSNP and 1000Genomes 
(http://www.1000genomes.org 29/07/2015) as a variant of unknown pathogenicity (rs570638580, 
MAF/minor allele: 0,0030/15). 
In silico tools for splicing prediction [15-19] reported c.341-81delT as pathogenic, because it 
generates a novel acceptor splicing site (AG in c.341-79 position). Four out of five tools (SSF, 
MaxEntScan, Gene Splicer, HSF) predicted a possible damaging role of the variant, with an 
alternative transcript 79bp longer r.(340_341ins341-79_341-1). This transcript would cause a 
reading frameshift and a truncated protein product (premature stop codon in exon 3: 
p.(Thr115Glufs*43)). 
 
Clinical characteristics of the patient homozygous for the  c.341-81delT HOGA1 variant 
 
The patient homozygous for the HOGA1 variant suffered from nephrocalcinosis since two 
months of life and died at four months of respiratory failure. Pox levels were normal (<1 mmol/L), 
while values of oxaluria/urinary creatinine were at the upper limit of the normal range (366 
µmol/mmol, nv for 0-6 months 325-360 µmol/mmol creatinine). Urinary calcium level was at the 
upper limit (uCa/uCr 0,56 mmol/mmol, nv for children < 1 years old: < 0.4 ). The renal function at 
four month of life was decreased (GFR 53 ml/min/1,73m2). His parents were not consanguineous. 
 
HOGA1 minigene assay 
 
In order to substantiate the predicted effect of the HOGA1 c.341-81delT variant on splicing we 
set up a minigene assay by cloning the intron 2 and exon 3 WT and variant sequences into a pSPL3 
vector (Fig.1). We expected a 391bp product resulting from the canonical splicing of HOGA1 exon 
3, a 471bp product from the alternative splicing generated by the deletion of T in c.341-81, and a 
263bp product resulting from the complete skipping of the inserted exon. Analysis of the cDNA 
showed only the presence of the two 263bp and 391bp bands, without any difference from WT (Fig. 
2).  
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Discussion 
 
The genetic basis of PH has been widened in recent years thanks to second line studies of AGXT 
negative patients, leading to identify PH2 and PH3[1,9].  
Nevertheless, a grey zone of cases in which suspicion based on clinical and biochemical 
findings is not confirmed by genetic testing still exists. The exact prevalence of this subset is 
currently unknown: several Authors reported the existence of undefined PH, but did not specify its 
prevalence or its clinical and genetic characteristics [1,3,20].  
In our cohort of patients, 80 resulted homozygous or compound heterozygous for AGXT 
mutations (83.3%) and one homozygous for a recurrent GRHPR mutation (1.1%). The 15.6% of the 
subjects with clinical PH suspicion resulted negative for any PH mutation. A recent UK study 
performed in 200 patients detected mutations in AGXT, GRHPR and HOGA1 in 50%, 8% and 8% of 
the patients respectively, while in 25% of the subjects no mutations were found [21]. In the USA, 
the analysis of 301 PH families revealed PH1 in 68.4% of them, PH2 in 9.3% and PH3 in 11.0% 
[20]. Compared to these results, PH1 in Italy seems to be far more frequent than the other PH types 
and, surprisingly, no Italian PH3 cases were identified up to now. 
 
In two patients two novel heterozygous AGXT-promoter variants, c.-647C>T and c.-424C>T 
were identified. We considered these variants not to be pathogenic since they do not lie in any 
known regulatory site. The validity of this conclusion is limited by the scanty literature on the 
AGXT promoter [22] that precludes comparison with previous studies. 
In one patient we detected a homozygous HOGA1 variant in intron 2 (c.341-81delT); we  could 
not perform genetic analysis of the HOGA1 variant in the patient's parents, since their DNA 
samples were not accessible. 
The c.341-81delT variant was predicted to affect splicing by in silico analysis and to introduce a 
frameshift change (p.Thr115Glufs*43) in isoform 1, disruptive of HOGA enzymatic activity. 
Indeed, the two minor HOGA isoforms described [23] include exons 1, 5, 6, 7 (isoform 2), and 
exons 1, 6 ,7 (isoform 3) but not exons 2 and 3, and are probably not functional. 
Even if the clinical characteristics of the c.341-81delT homozygous child were suggestive for 
PH3, a definite diagnosis cannot be established on a clinical basis alone. High urinary or plasma 
levels of dihydroxyglutarate and hydroxyoxoglutarate are indicative for PH3 [24], however the 
measurement of these metabolites is not yet performed in Italy.  
Neither RNA nor HOGA enzymological studies were possible because further biological 
samples of the patient were not available. To evaluate the effect of the variant, we set up a minigene 
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 9 
assay that in contrast to in silico predictions did not reveal any difference between the product of 
WT and c.341-81delT variant constructs. A possible explanation is that the power of the splicing 
site may be weaker than the canonical splicing site, so it could not be revealed by the simple 
minigene protocol in COS-7 and HEK293T cells.  
In the Primary Hyperoxaluria Database [25] it has been reported a HOGA1 c.341-82delA variant of 
undetermined significance: this description and our finding of the delT at c.341-81 highlight the 
potential pathogenic effect of variations in this region, as pointed out also by in silico tools 
predictions. No functional studies are available for the c.341-82delA and we believe that this report 
could be a useful base for further functional studies, despite the limitations of the minigene 
approach. 
 
Negative findings in our cohort of patients with a clinical diagnosis of hyperoxaluria may be 
ascribed to the presence of gross rearrangements (e.g. deletions/duplications), not identifiable by 
Sanger sequencing. However, such mutations implicate homozygosis of the SNPs haplotype and 
this is in contrast with our finding of heterozygous patients for several known AGXT, GRHPR and 
HOGA1 SNPs (Online Resource table 2). 
In our patients the presence of rare deep intronic splicing mutations in the three PH genes could 
not be excluded, as we did not sequence the whole intronic regions. However, such mutations are 
rarely searched in genetic testing and their prevalence is unknown; in literature few data regarding 
deep intronic mutations are reported: AGXT and GRHPR promoter analysis did not identify any 
causative mutations, while no Author has analyzed the whole intronic regions of the three PH genes 
[22,26].  
In four out of 15 cases we carried out genetic analysis on the basis of suggestive clinical history 
alone, although neither plasma nor urinary oxalate determinations were available since the 
collection was difficult; in these patients, secondary causes were excluded and a genetic etiology 
could be hypothesized because of their early onset of nephrolithiasis/nephrocalcinosis.  
These large number of undefined patients without a definitive diagnosis (11 patients) could be 
explained by other nephropathies or by the hypothesis of (an)other PH type(s), as postulated by 
several Authors [10,1,20], whose responsible gene/s is/are still unknown.  
Conversely, a putatively causative homozygous or compound heterozygous genotype may not 
always lead to phenotypic expression, and a recent extensive population genetic screen suggested an 
unexpectedly high frequency of such asymptomatic/underdiagnosed cases [20]. 
Oxalate metabolism is complex and not fully described, it is possible that more causative or 
modifier genes exist [1]. As candidates, the three human lactate dehydrogenases (LDHA, LDHB, 
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LDHC) have been proposed, because of their important role in excessive oxalate production: LDH 
is able to convert glyoxylate to oxalate, glyoxylate to glycolate and hydroxypyruvate to L-glycerate, 
using NAD(H) as cofactor [27]. Genetic variants in these three genes could influence the total LDH 
activity and the oxalate accumulation in PH patients. 
Another candidate involved in the pathogenesis of PH is the hepatocytes peroxisomal enzyme 
Glycolate Oxidase, (GO, encoded by HAO1 gene, OMIM *605023), also known as “hydroxyacid 
oxidase 1”. This enzyme catalyses the oxidation of glycolate to glyoxylate, the AGT substrate. The 
absence of GO activity causes isolated glycolic aciduria [28], but it could be hypothesized that 
hypermorphic genetic HAO1 variants could modulate the enzyme activity leading to a different 
production of glyoxylate, responsible of the variable phenotype in PH patients. 
 Finally, even a multigenic PH inheritance has been suggested [10,29], on the basis of the wide 
clinical variability among patients with the same AGXT genotype [30]. Therefore, further studies 
are needed to evaluate the relative contribution of genotype and environment in the development of 
the clinical phenotype. 
To explore this hypothesis and discover novel genes involved in oxalate metabolism, whole 
exome sequencing and SNPs array techniques and also further phenotype-genotype studies are 
needed. 
In conclusion, this study is the first report of HOGA1 genetic analysis in an Italian population. 
Despite PH3 being frequently reported both in Europe and in USA [10,20,21], no PH3 Italian cases 
were so far identified. It could be possible that some PH3 cases are missed because of the clinical 
remission of PH3 in adult age.  
In this study the analysis of GRHPR and HOGA1 genes after AGXT analysis did not increase the 
sensitivity of PH genetic testing. This negative report should prompt a closer interaction between 
clinicians and geneticians in evaluating the clinical and biochemical data and we propose a multiple 
step diagnostic algorithm (Fig 3) based on clinical and biochemical data to achieve this goal.    
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Compliance with ethical standard  
 
Ethical approval:  
All procedures performed in studies involving human participants were in accordance with the 
ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.  
This article does not contain any studies with animals performed by any of the authors.  
 
Informed consent:  
Informed consent was obtained from all  individual participants included in the study. 
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Figures and legend 
 
Fig.1  Minigene assay: the WT or mutant fragments of the human HOGA1 gene containing exon 3 
were cloned into the pSPL3 splicing vector to construct plasmids pSPL3-HOGA1-Exon3-WT and 
pSPL3-HOGA1-delT-Exon3. White boxes mark the pSPL3 exons A and B (derived from the B-
globin gene) and HOGA1 exon 3, and the adjacent black lines depict the flanking intronic sequence 
of pSPL3. The grey box represents the 79bp insertion expected from the generation of a novel 
splice-site by the c.341-81delT variant. The interrupted black lines mark the intronic sequences 
expected to be spliced out 
 
Fig. 2  1,8% agarose gel electrophoresis of the WT and c.341delT (delT) PCR products 
 
Fig. 3  Proposed algorithm for the diagnosis of primary hyperoxaluria. PH: Primary hyperoxaluria, 
Uox: Urinary Oxalate; Pox: Plasma Oxalate  
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SUPPLEMENTARY 
 
 
Minigene assay 
 
A 449 bp genomic fragment of DNA centered on the genomic change c.341-81delT and from a WT 
control sample was amplified, using the following primers:  
Forward 5’-ACTGGAATTCGTGGGTGGATGTGCAGGAT-3’  
Reverse 5’-GGTCAGGTAAGCCTCCCAAT-3’.  
 
 
Nested PCR 
 
A nested PCR of the c-DNA WT and c-DNA variant products was performed using the following 
primers: Fw 5’-AGTCGACCCAGCACTGAG; Rev 3’-CCAGGTCTTGGTGTAGTGG. 
Amplicons were separated on a TBE-agarose 1,8% gel and visualized after GelRed staining, the 
sequences were checked. 
 
Table 1  Clinical characteristics of patients. Y: years, mo: months, nd: not detected 
 
ID 
patient 
Sex Age 
Age at 
onset 
ESRD 
Uox 
uMol/mMol 
creatinine 
Age at 
Uox 
dosage 
Pox 
uMol/L 
Clinical characteristics 
1 M 44 y 32 y yes nd - 80 
bilateral nephrolithiasis, vascular 
calcifications, familiarity for nephrolithiasis  
2 F 13 y 9 y no 70 9 y 5,6 nephrolithiasis   
3 M 46 y 3 y yes nd - 16 nephrolithiasis since 3 years old, mono kidney 
4 M 4 y nd nd nd - nd nephrocalcinosis 
5 F 6 y 6 mo no 106 2 y 4 
nephrolithiasis, hematuria 
recurrent urinary infections   
6 M 
deceased 
at 4 mo 2 mo no 366 2 mo nd nephrocalcinosis 
7 F 16 y 9 y no 86 13 y nd nephrolithiasis, pyelonephritis 
8 F 3 y 4 mo no 115 8 mo 10 
nephrolithiasis, nephrocalcinosis, 
microhematuria, crystalluria 
9 F 5 y 2 y no 180 3 y nd 
nephrolithiasis  
familiarity for nephrolithiasis  
10 M 2 y 6 mo no 205 1 y nd 
bilateral nephrolithiasis, hematuria, familiarity 
for nephrolithiasis  
11 M 37 y 7 y yes nd - nd nephrolithiasis  
12 F 3 y 1 y no  190 2 y 6 nephrolithiasis, hematuria 
13 M 2 y 14 mo no 170 14 mo 9 
nephrocalcinosis, familiarity for 
nephrolithiasis  
14 F 13 y 9 y no nd - nd 
nephrolithiasis, left nephrectomy for 
pyonephrosis 
15 M 1 y 2 mo nd nd - nd 
nephrocalcinosis at 3 mo, recurrent urinary 
infections since 2 mo  
 Table 2  Results of genetic analysis for each patient; common SNPs founded in heterozygosis are reported in order to demonstrate the presence of 
both alleles for the heterozygous exons. AGXT haplotype: M major, m minor. Ex exon. WT: wild type. SNP: single nucleotide polymorphism. UV: 
unknown [pathogenicity] variant. SNPs code reference in dbSNP (http://www.ncbi.nlm.nih.gov/SNP/). 
 
  AGXT GRHPR HOGA1 
Patient 
ID 
Haplotype Exons in 
homozygosis 
Result SNP in heterozygosis Exons in 
homozygosis 
Result SNP in 
heterozygosis 
Exons in 
homozygosis 
1 Mm ex 3, 4, 5 WT rs10973332CA ex 2-9 WT rs11817730AG ex 1, 3, 5, 7 
rs7078003CT 
rs2297644CT 
2 MM all WT - all WT - all 
3 Mm ex 3-5; 7-9 WT rs35891798delG ex 2-8 WT - all 
rs72275009insCT 
4 Mm ex 3-5; 7-9 WT rs10973332CA ex 2-8 WT rs11527932GT ex 1, 2, 3, 4, 5, 7 
rs72275009insCT 
5 MM ex 1, 2, 6, 10 WT rs72275009insCT ex 2-8 WT - all 
6 MM ex 1-5, 7-10 WT rs72275009insCT ex 1-8 UV - all 
7 MM ex 1-5, 7-10 WT - all WT rs11817730AG ex 1, 3, 5, 6 
 rs7078003CT 
 rs 297644CT 
 rs12261752AC 
8 MM ex 1-5, 7-10 WT - all WT rs75929214CT ex 1, 2, 3, 5, 6 
 rs12261752CA 
9 MM ex 2, 3, 5-10 WT rs35891798etdelG ex 2-8 WT rs12261752CA ex 1, 2, 3, 5, 6 
rs76299266GA 
10 Mm ex 3, 5, 7, 8, 9 WT rs72275009insCT ex 1-8 WT rs75929214CT ex 1, 2, 3, 6 
rs2297643AG 
rs12261752CA 
         
         
Patient 
ID 
AGXT GRHPR HOGA1 
Haplotype Exons in 
homozygosis 
Result SNP in heterozygosis Exons in 
homozygosis 
Result SNP in 
heterozygosis 
Exons in 
homozygosis 
11 MM all WT - all WT rs2297643AG ex 1, 2, 3, 4 
rs115279832GT 
rs12261752CA 
 
12 
MM ex 2-3; 6-10 WT rs35891798delG ex 2-8 WT - all 
rs72275009insCT 
13 MM ex 1, 6, 11 WT - all WT rs75929214CT ex 1, 2, 3, 5, 6, 7 
14 MM ex 1-4; 7-10 WT - all WT rs75929214CT ex 1, 2, 5, 6, 7 
rs74155508GC 
15 MM ex 1-5; 7-10 
  
  
WT - all WT rs11817730AG ex 1, 3, 5, 6, 7 
rs75929214CT 
rs7078003CT 
rs2297644CT 
 
 
